Next Article in Journal
An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications
Next Article in Special Issue
The Expression of Embryonic Liver Development Genes in Hepatitis C Induced Cirrhosis and Hepatocellular Carcinoma
Previous Article in Journal
The Stroma—A Key Regulator in Prostate Function and Malignancy
Previous Article in Special Issue
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Cancers 2012, 4(2), 549-565; doi:10.3390/cancers4020549
Review

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

1
, 1
, 1
, 1
, 2
, 3
 and 1,*
Received: 8 May 2012; in revised form: 25 May 2012 / Accepted: 30 May 2012 / Published: 5 June 2012
(This article belongs to the Special Issue Advances and Research Progress in Hepatocellular Carcinoma)
View Full-Text   |   Download PDF [163 KB, uploaded 5 June 2012]   |   Browse Figures
Abstract: No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of sorafenib in Child-Pugh B patients with advanced HCC is currently ongoing. In the meantime, several trials are testing the role of sorafenib in early HCC (as adjuvant treatment after potentially curative loco-regional therapies) and in intermediate stage (exploring different modalities of integration of sorafenib with trans-arterial chemo-embolization). The results of all these trials will better define the potentiality and the boundaries of use of sorafenib in HCC patients.
Keywords: hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Di Maio, M.; Daniele, G.; Piccirillo, M.C.; Giordano, P.; Signoriello, G.; Daniele, B.; Perrone, F. Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers 2012, 4, 549-565.

AMA Style

Di Maio M, Daniele G, Piccirillo MC, Giordano P, Signoriello G, Daniele B, Perrone F. Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers. 2012; 4(2):549-565.

Chicago/Turabian Style

Di Maio, Massimo; Daniele, Gennaro; Piccirillo, Maria Carmela; Giordano, Pasqualina; Signoriello, Giuseppe; Daniele, Bruno; Perrone, Francesco. 2012. "Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials." Cancers 4, no. 2: 549-565.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert